American Society of Hirudotherapy

Thromboembolic disease in testicular germ cell tumors-real-world evidence of three Portuguese institutions

Research article published in Frontiers in oncology (2026)

Last Updated: November 1, 2026ASH Editorial · based on the books
Research article — evidence review: Off-label use means application outside the FDA-cleared indication. Clinical evidence (RCTs or systematic reviews) supports this use, but the FDA has not cleared it.Article reference: Content describes science, methodology, or organizational reference material — not a clinical efficacy claim.
Evidence: Research reportClinical LiteratureSafety & Infection ControlAlbuquerque J et al. · Frontiers in oncology, 2026

Abstract

INTRODUCTION: Testicular germ cell tumors (TGCTs) are highly curable malignancies with long-term overall survival (OS) exceeding 90%. Thromboembolic (TE) events are a relevant treatment-related complication, reported in approximately 10% of patients. This study aimed to evaluate the incidence, risk factors, and prognostic impact of TE in TGCT. METHODS: We performed a retrospective multicenter cohort study including 136 post-pubertal male patients with histologically confirmed TGCT treated between 2007 and 2021 at three Portuguese centers. The primary endpoint was to characterize the population of TGCT patients with TE. Secondary endpoints included TE incidence and its impact on OS and progression-free survival (PFS). Identification of clinical, pathological, and treatment-related factors associated with increased TE risk was an exploratory endpoint. RESULTS: Seven patients (5.1%) developed a TE event, all in advanced/recurrent disease (14.6% in this subgroup). No TE occurred in stage I patients, including those treated with adjuvant chemotherapy. Visceral metastases (pulmonary and extra-pulmonary) and poor IGCCCG prognosis were associated with TE (p < 0.05). All TE patients had a central venous catheter (CVC), although only two had catheter-related thrombosis (p = 0.019). For advanced stages, survival outcomes did not differ significantly, with 5-year OS of 71.4% vs. 86.2% (p = 0.22) and PFS of 47.6% vs. 75.5% (p = 0.23) in TE versus non-TE groups, respectively. Most events (86%) occurred within 30 days of chemotherapy initiation, with pulmonary embolism as the most frequent presentation. Neither the Khorana nor the ONKOTEV scores predicted TE. DISCUSSION: TE in TGCT occurred only in patients with advanced disease, was linked to tumor burden and CVC use, and was not predicted by current models. These findings highlight the need for TGCT-specific risk tools and prospective studies on risk-adapted prophylaxis.

Abstract sourced from PubMed (NCBI) for the cited record. See the original publication for the authoritative version.

Publication typeJournal Article

Summary

In 136 testicular germ cell tumor patients, 5.1% developed thromboembolism, all in advanced or recurrent disease (14.6% of that subgroup), associated with visceral metastases and central venous catheter use. Neither Khorana nor ONKOTEV scores predicted events.

Context

This retrospective multicenter cohort of 136 testicular germ-cell-tumor patients across three Portuguese centers found thromboembolic events in 5.1% overall (14.6% in advanced/recurrent disease, none in stage I), associated with visceral metastases, poor IGCCCG prognosis, and central-venous-catheter use, with most events occurring within 30 days of chemotherapy; neither Khorana nor ONKOTEV scores predicted them. Thematically, the study adds to the cancer-associated-thrombosis literature that defines the clinical problem space in which antithrombotic agents, including leech-derived candidates, are conceptually situated. Honest caveat: this is a small single-disease observational cohort with only seven events, focused on thrombosis epidemiology and risk prediction rather than treatment; it involves no leeches, makes no hirudotherapy claim, and supports no inference about leech-based therapy.

Citation

Reference (Vancouver style)

Albuquerque J, Oliveira M, Neto-Silva D, Margarido I, Correia J, Baptista C, et al. Thromboembolic disease in testicular germ cell tumors-real-world evidence of three Portuguese institutions. Front Oncol. 2026;16:1772608. doi:10.3389/fonc.2026.1772608. PMID: 41847697

Bibliographic details (authors, volume, pages, DOI) are taken from the PubMed record.

Added to ASH library: May 28, 2026 · Site last updated: November 1, 2026

This website provides educational information and does not constitute medical advice, diagnosis, or treatment recommendations. Medicinal leech therapy carries clinically meaningful risks and should be performed only by qualified clinicians under institutionally approved protocols. FDA 510(k) clearance for medicinal leeches is limited to specific indications; investigational and off-label discussions are labeled accordingly. For patient-specific guidance, consult a qualified healthcare provider.